BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 9530547)

  • 1. Raltitrexed. A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer.
    Gunasekara NS; Faulds D
    Drugs; 1998 Mar; 55(3):423-35. PubMed ID: 9530547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mature results from three large controlled studies with raltitrexed ('Tomudex').
    Cunningham D
    Br J Cancer; 1998; 77 Suppl 2(Suppl 2):15-21. PubMed ID: 9579851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of raltitrexed (Tomudex) in chemotherapy-pretreated patients with advanced colorectal cancer. Tomudex Cooperative Study Group.
    Sato A; Kurihara M; Horikoshi N; Aiba K; Kikkawa N; Shirouzu K; Mitachi Y; Sakata Y; Wakui A
    Anticancer Drugs; 1999 Sep; 10(8):741-8. PubMed ID: 10573207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group.
    Cocconi G; Cunningham D; Van Cutsem E; Francois E; Gustavsson B; van Hazel G; Kerr D; Possinger K; Hietschold SM
    J Clin Oncol; 1998 Sep; 16(9):2943-52. PubMed ID: 9738562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Phase I study of raltitrexed, an antifolate thymidylate synthase inhibitor, in adult patients with advanced solid tumors.
    Grem JL; Sorensen JM; Cullen E; Takimoto CH; Steinberg SM; Chen AP; Hamilton JM; Arbuck SG; McAtee N; Lawrence D; Goldspiel B; Johnston PG; Allegra CJ
    Clin Cancer Res; 1999 Sep; 5(9):2381-91. PubMed ID: 10499608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overview of the tolerability of 'Tomudex' (raltitrexed): collective clinical experience in advanced colorectal cancer.
    Zalcberg J
    Anticancer Drugs; 1997 Aug; 8 Suppl 2():S17-22. PubMed ID: 9376633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting thymidylate synthase in colorectal cancer: critical re-evaluation and emerging therapeutic role of raltitrexed.
    Avallone A; Di Gennaro E; Silvestro L; Iaffaioli VR; Budillon A
    Expert Opin Drug Saf; 2014 Jan; 13(1):113-29. PubMed ID: 24093908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Phase I study of raltitrexed (ZD-1694)].
    Horikoshi N; Aiba K; Fukuoka M; Akazawa S; Sakata Y; Furuse K; Kanamaru R; Kudoh S; Konishi T; Kurihara M; Niitani H; Furue H; Tsukagoshi S; Taguchi T; Yoshida S; Ota K; Kotake T; Wakui A
    Gan To Kagaku Ryoho; 1998 Nov; 25(13):2075-84. PubMed ID: 9838910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical efficacy of 'Tomudex' (raltitrexed) in advanced colorectal cancer.
    Kerr DJ
    Anticancer Drugs; 1997 Aug; 8 Suppl 2():S11-5. PubMed ID: 9376632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and preclinical pharmacokinetics of raltitrexed.
    Clarke SJ; Beale PJ; Rivory LP
    Clin Pharmacokinet; 2000 Dec; 39(6):429-43. PubMed ID: 11192475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New drugs in therapy of colorectal cancer: preclinical studies.
    Rustum YM; Cao S
    Semin Oncol; 1999 Dec; 26(6):612-20. PubMed ID: 10606254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A late phase II study of raltitrexed (ZD 1694) in chemotherapy-naive patients with advanced colorectal cancer].
    Nishisho I; Kikkawa N; Ebata T; Osanai H; Ujiie S; Mitachi Y; Tsutsui M; Sawai K; Nishiguchi Y; Yasutake K; Wakasugi H; Wakui A
    Gan To Kagaku Ryoho; 2000 Jan; 27(1):81-91. PubMed ID: 10660737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug resistance in colon cancer.
    Gorlick R; Bertino JR
    Semin Oncol; 1999 Dec; 26(6):606-11. PubMed ID: 10606253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy, tolerability and management of raltitrexed (Tomudex) monotherapy in patients with advanced colorectal cancer. a review of phase II/III trials.
    Cunningham D; Zalcberg J; Maroun J; James R; Clarke S; Maughan TS; Vincent M; Schulz J; González Barón M; Facchini T
    Eur J Cancer; 2002 Mar; 38(4):478-86. PubMed ID: 11872339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Raltitrexed in colorectal cancer].
    Comandone A; Oliva C; Dal Canton O; Boglione A; Bergnolo P
    Tumori; 2001; 87(1 Suppl 1):S53-4. PubMed ID: 11300026
    [No Abstract]   [Full Text] [Related]  

  • 16. 'Tomudex' (raltitrexed) development: preclinical, phase I and II studies.
    Judson IR
    Anticancer Drugs; 1997 Aug; 8 Suppl 2():S5-9. PubMed ID: 9376637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Raltitrexed: optimism and reality.
    Wilson KS; Malfair Taylor SC
    Expert Opin Drug Metab Toxicol; 2009 Nov; 5(11):1447-54. PubMed ID: 19863453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patterns of elevation of plasma 2'-deoxyuridine, a surrogate marker of thymidylate synthase (TS) inhibition, after administration of two different schedules of 5-fluorouracil and the specific TS inhibitors raltitrexed (Tomudex) and ZD9331.
    Ford HE; Mitchell F; Cunningham D; Farrugia DC; Hill ME; Rees C; Calvert AH; Judson IR; Jackman AL
    Clin Cancer Res; 2002 Jan; 8(1):103-9. PubMed ID: 11801545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Raltitrexed-based chemotherapy for advanced colorectal cancer.
    Liu Y; Wu W; Hong W; Sun X; Wu J; Huang Q
    Clin Res Hepatol Gastroenterol; 2014 Apr; 38(2):219-25. PubMed ID: 24388340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Raltitrexed (Tomudex) administration in patients with relapsed metastatic colorectal cancer after weekly irinotecan/5-Fluorouracil/Leucovorin chemotherapy.
    Tsavaris N; Kosmas C; Vadiaka M; Koufos C
    BMC Cancer; 2002; 2():2. PubMed ID: 11860608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.